FDA panel rejects psychedelic-assisted therapy for PTSD
Members of the group pointed to flawed study data and significant drug risks: US.
A US Food and Drug Administration advisory panel has voted against recommending the psychedelic MDMA for the treatment of PTSD.
In a 10-1 vote, the panel determined the evidence amassed so far fails to show the controversial drug’s benefits outweigh its risks, the Associated Press (AP) reported.
